NKTRNektar Therapeutics
NKTR
Nektar Therapeutics8,844
Mkt Cap
$2.82BVolume
690,055.0052W High
$109.0052W Low
$7.99PE Ratio
-8.46NKTR Fundamentals
Price
$86.46Prev Close
$85.04Open
$85.3150D MA
$76.83Beta
1.83Avg. Volume
1.2MEPS (Annual)
-$9.73P/B
19.61Rev/Employee
$876,698.41$616.46
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, May 1...
PR Newswire·9h ago
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire LOS ANGELES, May 1, 2026 LOS ANGELES, May 1, 2026 /PRNewswire/ -- Glancy...
PR Newswire·13h ago
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics...
PR Newswire·1d ago
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May...
PR Newswire·2d ago
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Trial Data Integrity: SueWallSt
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Trial Data Integrity: SueWallSt NKTR...
PR Newswire·2d ago
Nektar Therapeutics (NKTR) Expected to Announce Quarterly Earnings on Thursday
Nektar Therapeutics (NASDAQ:NKTR) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...
MarketBeat·2d ago
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Zalevsky Allegedly Overstated Enrollment Compliance: Levi & Korsinsky
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Zalevsky Allegedly Overstated Enrollment Compliance: Levi & Korsinsky NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek...
PR Newswire·3d ago
Moody Aldrich Partners LLC Decreases Stock Position in Nektar Therapeutics $NKTR
Moody Aldrich Partners LLC trimmed its stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 24.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,023 shares of the biopharmaceutical...
MarketBeat·3d ago
Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets Nektar to Announce Financial Results for the First Quarter on...
PR Newswire·3d ago
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm PR Newswire NEW YORK, April 28, 2026 NEW YORK, April 28...
PR Newswire·4d ago
<
1
2
...
>